Skip to main content
. 2023 May 5;42:115. doi: 10.1186/s13046-023-02683-4

Table 2.

Based on patient-derived tumor organoids formation and sensitivity test, 34 patients initiated the treatment. Treatment regimens and number of patients alive and without progression (PFS) at 2 months

Treatment Number of patients treated
(N = 34)
Number of patients with PFS at 2 months
(N = 17)
Gemcitabine-capecitabine 12 6
Vinorelbine-capecitabine 6 3
TAS-102 5 1
Temozolamide-irinotecan 3 2
FOLFIRI* 2 2
Regorafenib 2 0
Sorafenib 2 2
Epirubicin 1 1
Olaparib 1 0

* Bevacizumab was added in one case